These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 30285067

  • 21. Complement as an Immune Barrier in Platelet Transfusion Refractoriness.
    Meinke S, Karlström C, Höglund P.
    Transfus Med Rev; 2019 Oct; 33(4):231-235. PubMed ID: 31679761
    [Abstract] [Full Text] [Related]

  • 22. Response to random apheresis platelets versus HLA-selected platelets versus pooled platelets in HLA-sensitized patients.
    Gavva C, Barroso J, Gernsheimer T, Metcalf RA, Warner P, Pagano MB.
    Transfusion; 2019 Jul; 59(7):2276-2281. PubMed ID: 31032968
    [Abstract] [Full Text] [Related]

  • 23. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
    Wang J, Xia W, Deng J, Xu X, Shao Y, Ding H, Chen Y, Liu J, Chen D, Ye X, Santoso S.
    Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
    [Abstract] [Full Text] [Related]

  • 24. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
    Mirlashari MR, Vetlesen A, Nissen-Meyer LSH, Naper C, Tjønnfjord GE, Njerve IU, Ezligini F, Landmark BF, Meinke S, Sandgren P, Höglund P, Hetland G.
    Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
    [Abstract] [Full Text] [Related]

  • 25. Platelet transfusions: the problem of refractoriness.
    Murphy MF, Waters AH.
    Blood Rev; 1990 Mar; 4(1):16-24. PubMed ID: 2182145
    [Abstract] [Full Text] [Related]

  • 26. Successful transfusion of platelets "mismatched" for HLA antigens to alloimmunized thrombocytopenic patients.
    Duquesnoy RJ, Filip DJ, Rodey GE, Rimm AA, Aster RH.
    Am J Hematol; 1977 Mar; 2(3):219-26. PubMed ID: 596366
    [Abstract] [Full Text] [Related]

  • 27. Peripartum management of HLA alloimmune platelet refractoriness.
    Peña JR, Sudhof L, O'Brien B.
    Transfusion; 2018 Jul; 58(7):1583-1587. PubMed ID: 29664113
    [Abstract] [Full Text] [Related]

  • 28. Relationship of HLA and platelet-reactive antibodies in alloimmunized patients refractory to platelet therapy.
    Brubaker DB, Romine M.
    Am J Hematol; 1987 Dec; 26(4):341-52. PubMed ID: 3687931
    [Abstract] [Full Text] [Related]

  • 29. Platelet refractoriness--practical approaches and ongoing dilemmas in patient management.
    Stanworth SJ, Navarrete C, Estcourt L, Marsh J.
    Br J Haematol; 2015 Nov; 171(3):297-305. PubMed ID: 26194869
    [Abstract] [Full Text] [Related]

  • 30. A prospective randomized trial of HLA-matched versus mismatched single-donor platelet transfusions in cancer patients.
    Messerschmidt GL, Makuch R, Appelbaum F, Ungerleider RS, Abrams R, O'Donnell J, Holohan TV, Fontana J, Wright D, Anagnou NP.
    Cancer; 1988 Aug 15; 62(4):795-801. PubMed ID: 3293762
    [Abstract] [Full Text] [Related]

  • 31. Independent roles for platelet crossmatching and HLA in the selection of platelets for alloimmunized patients.
    Friedberg RC, Donnelly SF, Mintz PD.
    Transfusion; 1994 Mar 15; 34(3):215-20. PubMed ID: 8146893
    [Abstract] [Full Text] [Related]

  • 32. Anti-HLA Class I alloantibodies in platelet transfusion refractoriness: From mechanisms and determinants to therapeutic prospects.
    Couvidou A, Rojas-Jiménez G, Dupuis A, Maître B.
    Front Immunol; 2023 Mar 15; 14():1125367. PubMed ID: 36845153
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Human leukocyte antigen (HLA)-incompatible mean fluorescence intensity-selected platelet products have corrected count increments similar to HLA antigen-matched platelets.
    Karafin MS, Schumacher C, Zhang J, Simpson P, Johnson ST, Pierce KL.
    Transfusion; 2021 Aug 15; 61(8):2307-2316. PubMed ID: 34075590
    [Abstract] [Full Text] [Related]

  • 36. Utility of cross-matched platelet transfusions in patients with hypoproliferative thrombocytopenia: a systematic review.
    Vassallo RR, Fung M, Rebulla P, Duquesnoy R, Saw CL, Slichter SJ, Tanael S, Shehata N, International Collaboration for Guideline Development, Implementation and Evaluation for Transfusion Therapies.
    Transfusion; 2014 Apr 15; 54(4):1180-91. PubMed ID: 24032995
    [Abstract] [Full Text] [Related]

  • 37. A real-life evaluation of two platelet cross-matching programmes for the treatment of patients refractory to platelet transfusions.
    Revelli N, Villa MA, Olivero B, Bresciani S, Flores M, Marini M, Pizzi MN, Prati D, Rebulla P.
    Vox Sang; 2019 Jan 15; 114(1):73-78. PubMed ID: 30523641
    [Abstract] [Full Text] [Related]

  • 38. Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions.
    Waterman HR, Kapp LM, Munday A, Odem-Davis K, Zimring JC.
    Transfusion; 2016 Jan 15; 56(1):91-100. PubMed ID: 26400622
    [Abstract] [Full Text] [Related]

  • 39. Antibodies to human platelet antigens form a significant proportion of platelet antibodies detected in Indian patients with refractoriness to platelet transfusions.
    Abraham AS, Chacko MP, Fouzia NA, Srivastava A, Daniel D.
    Transfus Med; 2018 Oct 15; 28(5):392-397. PubMed ID: 29460307
    [Abstract] [Full Text] [Related]

  • 40. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
    Figueiredo C, Blaszczyk R.
    J Stem Cells; 2014 Oct 15; 9(3):149-61. PubMed ID: 25157449
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.